Image source: © Timonschneider | Megapixl.com
Highlights
- CSL develops, manufactures, markets and distributes biopharmaceutical products and services
- In 1HFY24, the company witnessed 12% YoY rise in revenue to USD 8,053 million
- State Street Global Advisors Australia Ltd. has maximum stake in the company with a shareholding of ~4.99%
CSL Limited (ASX: CSL) is an ASX-listed biotechnology firm which is involved in research, development, marketing, manufacturing and distribution of biopharmaceutical products and services. The company provides innovative life-saving medicines in over 100 countries.
In the first half of the financial year 2024 (1HFY24), the company recorded 12% YoY rise in its total revenue to USD 8,053 million, 13% YoY increase in NPATA to USD 2,017 million and 14% YoY increase in revenue from CSL Behring business to USD 5,238 million.
The reported period saw a 23% YoY jump in sales of immunoglobulin products, 8% YoY increase in sales of albumin and 8% YoY growth in sales of Haemophilia products.

Recent business update
Through an ASX update dated 23 February 2024, the company notified that Ms. Samantha Lewis had bought 114 rights under the CSL Limited Non-Executive Director Rights Plan for AUD 32,190.63.
Top 10 shareholders of CSL
The top 10 shareholders of CSL have around 18.89% shareholding in the company, while the top four have nearly 12.70% shareholding. The Vanguard Group, Inc. and State Street Global Advisors Australia Ltd. have highest stake in the company with a shareholding of ~4.99% and ~3.18%, respectively.
Outlook
In FY24, the company expects to see nearly 9% – 11% YoY increase in its revenue on constant currency basis and expects its underlying profit to fall in the range of around USD 2.9 billion to USD 3 billion, at constant currency, representing nearly 13-17% YoY growth.
The company aims to achieve double-digit earnings growth on an annual basis over the medium term.
Growth in the immunoglobulins franchise is anticipated to continue backed by the growing patient demand. The company has taken up multiple initiatives to support continued expansion in the gross margin of CSL Behring.
Share performance of CSL
CSL shares closed 0.247% lower at AUD 282.30 apiece on 6 March with a market capitalization of AUD 136.72 billion. With this, in the past one year, CSL’s share price has decreased by 4.91%, and in the past three months, it has increased by 5.54%.
The 52-week high of CSL is AUD 312.99, recorded on 6 June 2023, while the 52-week low is AUD 228.65, recorded on 30 October 2023.

CSL Daily Technical Chart, Source: REFINITIV
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 06 March 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.